Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
583 Leser
Artikel bewerten:
(2)

Agfa-Gevaert comments on its achievements in the third quarter of 2019 - Regulated information - November 6, 2019 - 7:45 a.m. CET

?

Milestones in the transformation process

· Auction process for part of the activities of Agfa HealthCare launched in third quarter

· Implementation of offset alliance with Lucky HuaGuang Graphics is running according to plan

Financial results

· Top line growth based on good performances of most of the growth engines and the effects of the offset alliance

· Adjusted EBIT at 24 million Euro (including IFRS 16)

· Net result at minus 4 million Euro (including IFRS 16)

· Net debt decrease versus previous quarter due to working capital improvement

Mortsel (Belgium), November 6, 2019 - Agfa-Gevaert today commented on its achievements in the third quarter of 2019.

MILESTONES IN THE AGFA-GEVAERT GROUP'S TRANSFORMATION PROCESS

"In the third quarter, we launched the auction process for the sale of part of the IT activities of Agfa HealthCare. It is progressing according to plan and we hope to finish this auction process by the end of the year.

The implementation of the offset alliance with Lucky HuaGuang Graphics is also running as expected. We continued to expand the common sales platform into more regions within China. We started to recognize sales from the alliance in our top line in the second quarter and this accelerated in the past few months. This top line impact is expected to continue to grow gradually in the quarters to come," said Christian Reinaudo, President and CEO of the Agfa-Gevaert Group.

FINANCIAL RESULTS

"For the second quarter in a row, we are able to report top line growth. Most of our growth engines performed well and the hardcopy range continued to benefit from the reorganization of the Chinese distribution channels. Within the HealthCare IT division especially the HealthCare Information Solutions business performed well. As announced in August, the termination of the reseller activities related to inkjet media in the USA impacted the top line of the Digital Print & Chemicals division.

The program we initiated to improve our trade working capital is starting to bear fruit. In the third quarter, the working capital improvements resulted in a stronger cash generation and a decline in net financial debt," said Christian Reinaudo, President and CEO of the Agfa-Gevaert Group.

Statement on IFRS 16 and 2018 restated profit and loss numbers

Several factors influence the way the Agfa-Gevaert Group reports its financial results as from the first quarter of 2019.

The activities of the Agfa-Gevaert Group have been regrouped into four divisions. To allow for a more accurate assessment of the business performances, some costs of corporate functions at Group level (e.g. Investor Relations, Corporate Finance, Internal Audit, the newly created Innovation Office,…) are no longer attributed to the business divisions. For Q3 2019, these costs amounted to 3.7 million Euro (Q3 2018: 3.7 million Euro). These costs are now grouped under Corporate Services. To allow comparison, the Q3 2018 profit and loss numbers have been restated.

As from 2019, the Agfa-Gevaert Group has adopted the IFRS 16 accounting rules. However, to allow correct comparison with Q3 2018, the tables below present the Q3 2019 profit and loss numbers excluding the impact of IFRS 16.

Agfa-Gevaert Group - Q3 2019

in million EuroQ3 2019
(excl.
IFRS 16)
Q3 2018

Restated
(excl.
IFRS 16)
% change

(excl.
FX effects)
Revenue 553 539 2.6% (1.1%)
Gross profit (*) 171 171 -0.1%
% of revenue 31.0% 31.8%
Adjusted EBITDA (*) 38** 35 9.1%
% of revenue 6.9% 6.5%
Adjusted EBIT (*) 24** 21 11.1%
% of revenue 4.3% 4.0%
Result from operating activities 17 6 172.8%

(*) before restructuring and non-recurring items

(**) Q3 2019 Adjusted EBITDA including IFRS 16: 48 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: 24 million Euro

Continuing the positive evolution of the first half of the year, the Agfa-Gevaert Group's top line grew by 2.6% (1.1% excluding exchange rate effects) in the third quarter of 2019. Most growth engines, as well as the hardcopy product line, contributed to the top line growth. The Digital Print & Chemicals division's top line was impacted by the decision to discontinue the reseller activities related to inkjet media in the USA, which was announced in August. Excluding the effect of this decision, the Group's revenue growth would amount to 5.7%.

The Group's gross profit margin decreased from 31.8% of revenue in the third quarter of 2018 to 31.0%. The main reasons were adverse product and regional mix effects, the negative impact of high aluminum costs, as well as the dilutive effect related to the consolidation of the sales coming from the alliance with Lucky HuaGuang Graphics.

Selling and General Administration expenses decreased from 115 million Euro (21.4% of revenue) in the third quarter of 2018 to 111 million Euro (20.1% of revenue).

R&D expenses amounted to 37 million Euro (6.6% of revenue), versus 32 million Euro (6.0% of revenue) in the third quarter of 2018.

Excluding the effects of IFRS 16, adjusted EBITDA improved from 6.5% of revenue in the third quarter of 2018 to 6.9%. Adjusted EBIT reached 4.3% of revenue, versus 4.0% in the third quarter of 2018.

Restructuring and non-recurring items resulted in an expense of 7 million Euro, versus an expense of 15 million Euro in the third quarter of 2018, when the impact of costs related to the Group's transformation efforts were more significant.

The net finance costs (including IFRS 16) amounted to 11 million Euro.

Income tax expenses (including IFRS 16) amounted to 10 million Euro, versus 0 million Euro in 2018 and included some effects of the carve-out of HealthCare IT.

As a result of the elements mentioned above, the Agfa-Gevaert Group posted a net loss of minus 4 million Euro (including IFRS 16).

Financial position and cash flow (including IFRS 16)

  • At the end of September 2019, total assets were 2,399 million Euro (comprising right-of-use assets compliant with the new accounting standard on leases: 112 million Euro at the end of September 2019), compared to 2,367 million Euro at the end of 2018.
  • Trade working capital moved from 653 million Euro (29% of sales) at the end of 2018 to 633 million Euro (28% of sales) at the end of September 2019.
  • Net financial debt amounted to 276 million Euro (or 161 million Euro excluding the impact of IFRS 16), versus 144 million Euro at the end of 2018.
  • Net cash from operating activities amounted to 50 million Euro.

Offset Solutions - Q3 2019

in million EuroQ3 2019
(excl.
IFRS 16)
Q3 2018

Restated
(excl.
IFRS 16)
% change

(excl.
FX effects)
Revenue 212 204 3.6% (1.9%)
Adjusted EBITDA (*) 3.4** 5.9 -42.7%
% of revenue 1.6% 2.9%
Adjusted EBIT (*) (0.8)** 0.6
% of revenue (0.4)% 0.3%

(*) before restructuring and non-recurring items

(**) Q3 2019 Adjusted EBITDA including IFRS 16: 6.3 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: minus 0.7 million Euro

As the alliance with Lucky HuaGuang Graphics is coming up to speed, the Offset Solutions division was able to post a 3.6% top line growth (1.9% excluding currency effects) compared to the third quarter of 2018. It is expected that the effects of the alliance will become increasingly visible in the coming quarters.

The Offset Solutions division is active in structurally declining markets. The offset industry is marked by the strong decline in demand for analog prepress technology and decreasing newspaper and commercial print volumes. The division also continues to face price pressure, caused by intense competition.

The Offset Solutions division's gross profit margin decreased from 24.6% of revenue in the third quarter of 2018 to 20.7%. Half of the decrease was due to the dilutive effect related to the consolidation of the sales coming from the alliance with Lucky HuaGuang Graphics. In addition, adverse product and regional mix effects, increased idle time due to overcapacity and high aluminum costs also impacted the gross profit margin. Excluding the effects of IFRS 16, adjusted EBITDA amounted to 3.4 million Euro (1.6% of revenue), versus 5.9 million Euro (2.9% of revenue) in the third quarter of 2018 and adjusted EBIT amounted to minus 0.8 million Euro (minus 0.4% of revenue), versus 0.6 million Euro (0.3% of revenue).

In the third quarter, HP Indigo and Agfa announced a unique variable design security solution for brand protection and security printing. HP Indigo Secure Studio Powered by Agfa creates unique graphic designs with endless variations.


Digital Print & Chemicals - Q3 2019

in million EuroQ3 2019
(excl.
IFRS 16)
Q3 2018
Restated

(excl.
IFRS 16)
% change

(excl.
FX effects)
Revenue 85 98 -13.0% (-14.0%)
Adjusted EBITDA (*) 2.8** 7.6 -63.1%
% of revenue 3.3% 7.8%
Adjusted EBIT (*) 1.1** 6.2 -82.6%
% of revenue 1.3% 6.3%

(*) before restructuring and non-recurring items

(**) Q3 2019 Adjusted EBITDA including IFRS 16: 4.0 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: 1.1 million Euro

Mainly as a result of the discontinuation of the reseller activities related to inkjet media in the USA, the top line of the Digital Print & Chemicals division decreased by 13.0% (14.0% excluding currency effects) compared to the third quarter of 2018. In inkjet, the ink product ranges performed well, whereas equipment sales were weaker following a strong second quarter.

In the Industrial Films and Foils segment, the Synaps Synthetic Paper range and the Security range performed well. The Electronic Print segment's Orgacon Electronic Materials range also reported good sales figures.

The division's gross profit margin decreased from 27.1% of revenue in the third quarter of 2018 to 26.8%. Excluding the effects of IFRS 16, the division's adjusted EBITDA reached 2.8 million Euro (3.3% of revenue), versus 7.6 million Euro (7.8% of revenue) in the third quarter of 2018. Adjusted EBIT amounted to 1.1 million Euro (1.3% of revenue), versus 6.2 million Euro (6.3% of revenue). With the main impact of the strategic alliance for UV digital packaging inks with Siegwerk Druckfarben coming to an end, the third quarter 2019 adjusted EBITDA margin was negatively influenced. Excluding this effect, the adjusted EBITDA margin would have remained stable.

Early October, Agfa announced that its Jeti Mira 2732 HS LM LED printing system was named as the winner of the 2019 Product of the Year award by the Specialty Graphic Imaging Association (SGIA) in the UV/Latex Flatbed ($200,000-$500,000) category.


Radiology Solutions - Q3 2019

in million EuroQ3 2019
(excl.
IFRS 16)
Q3 2018
Restated

(excl.
IFRS 16)
% change

(excl.
FX effects)
Revenue 132 118 11.8% (9.8%)
Adjusted EBITDA (*) 19.7** 14.5 35.2%
% of revenue 14.9% 12.4%
Adjusted EBIT (*) 15.6** 11.2 38.8%
% of revenue 11.9% 9.5%

(*) before restructuring and non-recurring items

(**) Q3 2019 Adjusted EBITDA including IFRS 16: 22.0 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: 15.8 million Euro

The Radiology Solutions division's revenue increased by 11.8% compared to the third quarter of 2018 based on double-digit growth for both the hardcopy business and the Direct Radiography solutions range. The hardcopy business continued to benefit from the effects of the reorganization of the distribution channels in China. The top line growth of the innovative Direct Radiography solutions range was partly based on increased service revenues.

Due to regional and product/mix effects, the division's gross profit margin decreased from 35.8% of revenue in the third quarter of 2018 to 34.9%. Excluding the effects of IFRS 16, adjusted EBITDA increased from 14.5 million Euro (12.4% of revenue) in the third quarter of 2018 to 19.7 million Euro (14.9% of revenue). Adjusted EBIT reached 15.6 million Euro (11.9% of revenue), versus 11.2 million Euro (9.5% of revenue) in the previous year.

HealthCare IT - Q3 2019

in million EuroQ3 2019
(excl.
IFRS 16)
Q3 2018
Restated

(excl.
IFRS 16)
% change

(excl.
FX effects)
Revenue 125 119 5.0% (3.7%)
Adjusted EBITDA (*) 16.0** 10.6 50.4%
% of revenue 12.8% 8.9%
Adjusted EBIT (*) 11.7** 7.1 64.6%
% of revenue 9.3% 6.0%

(*) before restructuring and non-recurring items

(**) Q3 2019 Adjusted EBITDA including IFRS 16: 19.9 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: 12.0 million Euro

The HealthCare IT division posted substantial top line growth, based on the good performance of the HealthCare Information Solutions business especially.

Like in the previous quarters, the HealthCare Information Solutions business again recorded solid top line growth, confirming its leading position in the German speaking countries of Europe and in France.

The gross profit margin improved from 44.2% of revenue in the third quarter of 2018 to 47.1%. Significant service efficiency improvements, strong software sales and the decision to wind down the Imaging IT Solutions from certain less sustainable markets had a positive effect on profitability. Excluding the effects of IFRS 16, adjusted EBITDA increased from 10.6 million Euro (8.9% of revenue) in the third quarter of 2018 to 16.0 million Euro (12.8% of revenue). Adjusted EBIT reached 11.7 million Euro (9.3% of revenue), versus 7.1 million Euro (6.0% of revenue) in the previous year.

Corporate Services - Q3 2019

in million EuroQ3 2019
(excl.
IFRS 16)
Q3 2018

Restated
(excl.
IFRS 16)
Adjusted EBITDA (*) (3.7)** (3.7)
Adjusted EBIT (*) (3.7)** (3.7)

(*) before restructuring and non-recurring items

(**) Q3 2019 Adjusted EBITDA including IFRS 16: minus 3.7 million Euro
Q3 2019 Adjusted EBIT including IFRS 16: minus 3.7 million Euro

To allow for a more accurate assessment of the business performances, costs of corporate functions at Group level (e.g. Investor Relations, Corporate Finance, Internal Audit, the newly created Innovation Office,…) are grouped under Corporate Services.


Results after nine months

Agfa-Gevaert Group - year to date

in million Euro9M 2019
(excl.
IFRS 16)
9M 2018

Restated
(excl.
IFRS 16)
% change

(excl.
FX effects
Revenue 1,668 1,647 1.3% (-0.2%)
Gross profit (*) 542 529 2.3%
% of revenue 32.5% 32.1%
Adjusted EBITDA (*) 127** 121 4.8%
% of revenue 7.6% 7.3%
Adjusted EBIT (*) 85** 81 4.6%
% of revenue 5.1% 4.9%
Result from operating activities 63 52 19.6%

(*) before restructuring and non-recurring items

(**) 9M 2019 Adjusted EBITDA including IFRS 16: 157 million Euro
9M 2019 Adjusted EBIT including IFRS 16: 86 million Euro

Offset Solutions - year to date

in million Euro9M 2019
(excl.
IFRS 16)
9M 2018

Restated
(excl.
IFRS 16)
% change

(excl.
FX effects)
Revenue 617 632 -2.2% (-4.0%)
Adjusted EBITDA (*) 13.0** 30.8 -58.0%
% of revenue 2.1% 4.9%
Adjusted EBIT (*) (0.7)** 14.7
% of revenue (0.1)% 2.3%

(*) before restructuring and non-recurring items

(**) 9M 2019 Adjusted EBITDA including IFRS 16: 21.5 million Euro
9M 2019 Adjusted EBIT including IFRS 16: minus 0.5 million Euro

Digital Print & Chemicals - year to date

in million Euro9M 2019
(excl.
IFRS 16)
9M 2018
Restated

(excl.
IFRS 16)
% change

(excl.
FX effects)
Revenue 294 292 0.6% (-1.3%)
Adjusted EBITDA (*) 23.7** 21.5 10.4%
% of revenue 8.1% 7.4%
Adjusted EBIT (*) 18.5** 17.1 7.9%
% of revenue 6.3% 5.9%

(*) before restructuring and non-recurring items

(**) 9M 2019 Adjusted EBITDA including IFRS 16: 27.2 million Euro
9M 2019 Adjusted EBIT including IFRS 16: 18.6 million Euro


Radiology Solutions - year to date

in million Euro9M 2019
(excl.
IFRS 16)
9M 2018
Restated

(excl.
IFRS 16)
% change

(excl.
FX effects)
Revenue 383 364 5.2% (4.7%)
Adjusted EBITDA (*) 56.8** 47.3 20.2%
% of revenue 14.9% 13.0%
Adjusted EBIT (*) 44.7** 38.0 17.5%
% of revenue 11.7% 10.5%

(*) before restructuring and non-recurring items

(**) 9M 2019 Adjusted EBITDA including IFRS 16: 63.4 million Euro
9M 2019 Adjusted EBIT including IFRS 16: 44.9 million Euro

HealthCare IT - year to date

in million Euro9M 2019
(excl.
IFRS 16)
9M 2018
Restated

(excl.
IFRS 16)
% change

(excl.
FX effects)
Revenue 374 360 3.9% (2.3%)
Adjusted EBITDA (*) 45.3** 32.3 40.1%
% of revenue 12.1% 9.0%
Adjusted EBIT (*) 34.5** 22.1 56.0%
% of revenue 9.2% 6.1%

(*) before restructuring and non-recurring items

(**) 9M 2019 Adjusted EBITDA including IFRS 16: 57.1 million Euro
9M 2019 Adjusted EBIT including IFRS 16: 35.3 million Euro

Corporate Services - year to date

in million Euro9M 2019
(excl.
IFRS 16)
9M 2018
Restated

(excl.
IFRS 16)
Adjusted EBITDA (*) (12.1)** (10.9)
Adjusted EBIT (*) (12.2)** (10.9)

(*) before restructuring and non-recurring items

(**) 9M 2019 Adjusted EBITDA including IFRS 16: minus 12.1 million Euro
9M 2019 Adjusted EBIT including IFRS 16: minus 12.2 million Euro

End of message

Management Certification of Financial Statements and Quarterly Report

This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of 14 November 2007 and in effect as of 2008.

"The Board of Directors and the Executive Committee of Agfa-Gevaert NV, represented by Mr. Klaus Röhrig, Chairman of the Board of Directors, Mr. Christian Reinaudo, President and CEO, and Mr. Dirk De Man, CFO, jointly certify that, to the best of their knowledge, the consolidated financial statements included in the report and based on the relevant accounting standards, fairly present in all material respects the financial condition and results of Agfa-Gevaert NV, including its consolidated subsidiaries. Based on our knowledge, the report includes all information that is required to be included in such document and does not omit to state all necessary material facts."

Statement of risk

This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of 14 November 2007 and in effect as of 2008.

"As with any company, Agfa is continually confronted with - but not exclusively - a number of market and competition risks or more specific risks related to the cost of raw materials, product liability, environmental matters, proprietary technology or litigation."

Key risk management data is provided in the annual report available on www.agfa.com.

Contact:

Viviane Dictus
Director Corporate Communication
Septestraat 27
2640 Mortsel - Belgium
T +32

Johan Jacobs

Corporate Press Relations Manager
T +32 (0)3/444 80 15

E johan.jacobs@agfa.com

The full press release and financial information is also available on the company's website: www.agfa.com


Consolidated Statement of Profit or Loss (in million Euro)

Unaudited, consolidated figures following IFRS accounting policies.

Q3 2019

Q3 2018

9M 2019

9M 2018

Revenue5535391,6681,647
Cost of sales (382) (368) (1,127) (1,118)
Gross profit172171541529
Selling expenses (72) (79) (230) (240)
Administrative expenses (42) (42) (129) (128)
R&D expenses (36) (32) (108) (105)
Net impairment loss on trade and other receivables, including contract assets (1) (2) (4) (3)
Other operating income 17 11 42 46
Other operating expenses (19) (20) (48) (46)
Results from operating activities1866453
Interest income (expense) - net(2)(2)(6)(5)
Interest income - 1 1 1
Interest expense (2) (3) (8) (7)
Other finance income (expense) - net(9)(9)(25)(26)
Other finance income 1 2 5 2
Other finance expense (10) (11) (29) (27)
Net finance costs(11)(11)(31)(31)
Share of profit of associates, net of tax - - (1) (1)
Profit (loss) before income taxes7(5)3321
Income tax expenses (10) - (24) (13)
Profit (loss) for the period(4)(5)98
Profit (loss) attributable to:
Owners of the Company (5) (5) 6 4
Non-controlling interests 1 1 3 4
Results from operating activities 18 6 64 53
Restructuring and non-recurring items (7) (15) (22) (28)
Adjusted EBIT 24 21 86 81
Earnings per share (Euro) (0.03) (0.04) 0.04 0.02

The Group has initially applied IFRS 16 at January 1, 2019, using the modified retrospective approach. Under this approach, comparative information is not restated. There has been no impact to retained earnings of initially applying IFRS 16 at the date of initial application.

Consolidated Statements of Comprehensive Income for the nine months ending September 2018 / September 2019 (in million Euro)

Unaudited, consolidated figures following IFRS accounting policies

9M 2019

9M 2018
Profit / (loss) for the period98
Other Comprehensive Income, net of tax
Items that are or may be reclassified subsequently to profit or loss:
Exchange differences:17(1)
Exchange differences on translation of foreign operations 17 (1)
Cash flow hedges: 4(14)
Effective portion of changes in fair value of cash flow hedges (9) (8)
Changes in the fair value of cash flow hedges reclassified to profit or loss 3 (5)
Adjustments for amounts transferred to initial carrying amount of hedged items 11 (5)
Income taxes - 4
Items that will not be reclassified subsequently to profit or loss:-(2)
Equity investments at fair value through OCI - change in fair value - (1)
Remeasurements of the net defined benefit liability - -
Income tax on remeasurements of the net defined benefit liability - (1)
Total other Comprehensive Income for the period, net of tax20(17)
Total Comprehensive Income for the period attributable to:29(9)
Owners of the Company 26 (13)
Non-controlling interests 3 4


Consolidated Statements of Comprehensive Income for the quarter ending September 2018 / September 2019 (in million Euro)

Unaudited, consolidated figures following IFRS accounting policies

Q3 2019

Q3 2018
Profit / (loss) for the period(4)(5)
Other Comprehensive Income, net of tax
Items that are or may be reclassified subsequently to profit or loss:
Exchange differences:10-
Exchange differences on translation of foreign operations 10 -
Cash flow hedges: (1)(3)
Effective portion of changes in fair value of cash flow hedges (5) (3)
Changes in the fair value of cash flow hedges reclassified to profit or loss 1 -
Adjustments for amounts transferred to initial carrying amount of hedged items 4 -
Income taxes - -
Items that will not be reclassified subsequently to profit or loss:(1)-
Equity investments at fair value through OCI - change in fair value (1) -
Remeasurements of the net defined benefit liability - -
Income tax on remeasurements of the net defined benefit liability - -
Total other Comprehensive Income for the period, net of tax7(3)
Total Comprehensive Income for the period attributable to:4(8)
Owners of the Company 2 (8)
Non-controlling interests 2 -


Consolidated Statement of Financial Position (in million Euro)

Unaudited, consolidated figures following IFRS accounting policies.



30/09/2019

31/12/2018

Non-current assets1,1471,019
Goodwill 528 523
Intangible assets 88 93
Property, plant & equipment 167 174
Right-of-use assets 112 -
Investments in associates 4 4
Other financial assets 8 9
Trade receivables 21 16
Receivables under finance leases 80 62
Other assets 23 24
Deferred tax assets 116 114
Current assets1,2521,348
Inventories 512 498
Trade receivables 379 420
Contract assets 120 105
Current income tax assets 70 71
Other tax receivables 19 25
Receivables under finance lease 17 30
Other receivables 11 14
Other assets 30 34
Derivative financial instruments 1 1
Cash and cash equivalents 81 141
Non-current assets held for sale 10 10
TOTAL ASSETS2,3992,367




30/09/2019

31/12/2018

Total equity322290
Equity attributable to owners of the company277252
Share capital 187 187
Share premium 210 210
Retained earnings 862 854
Other reserves (90) (93)
Translation reserve 4 (9)
Post-employment benefits: remeasurements of the net defined benefit liability (897) (897)
Non-controlling interests 45 38
Non-current liabilities1,3281,336
Liabilities for post-employment and long-term termination benefit plans 1,009 1,066
Other employee benefits 14 13
Loans and borrowings 276 219
Provisions 5 9
Deferred tax liabilities 21 22
Trade payables - 2
Contract liabilities 1 3
Other non-current liabilities 1 2
Current liabilities749741
Loans and borrowings 81 66
Provisions 44 52
Trade payables 227 217
Contract liabilities 171 163
Current income tax liabilities 47 47
Other tax liabilities 20 27
Other payables 13 17
Employee benefits 131 134
Other current liabilities 4 4
Derivative financial instruments 10 13
TOTAL EQUITY AND LIABILITIES2,3992,367

The Group has initially applied IFRS 16 at January 1, 2019, using the modified retrospective approach.

Under this approach, comparative information is not restated.

There has been no impact to retained earnings of initially applying IFRS 16 at the date of initial application.
Consolidated Statement of Cash Flows (in million Euro) Unaudited, consolidated figures following IFRS accounting policies.

9M 2019

9M 2018

Q3 2019

Q3 2018

Profit (loss) for the period 9 8 (4) (5)
Income taxes 24 13 10 -
Share of (profit)/loss of associates, net of tax 1 1 - -
Net finance costs 31 31 11 11
Operating result6452186
Depreciation, amortization and impairment losses 47 40 19 14
Depreciation, amortization IFRS 16 29 - 10 -
Impairment losses on right-of-use assets (*) 4 - - -
Exchange results and changes in fair value of derivates 5 (4) 2 (5)
Recycling of hedge reserve 3 (5) - (5)
Government grants and subsidies (8) (12) (2) (6)
(Gains)/losses on the sale of intangible assets and PP&E and remeasurement of leases (6) (4) (6) -
Expenses for defined benefit plans & long-term termination benefits 29 30 7 6
Accrued expenses for personnel commitments 66 67 25 27
Write-downs/reversal of write-downs on inventories 10 11 2 3
Impairments/reversal of impairments on receivables 4 4 1 2
Additions/reversals of provisions 12 15 4 9
Other non-cash expenses1161013530
Change in inventories (10) (82) 20 (26)
Change in trade receivables 37 15 11 (18)
Change in contract assets (13) (17) - (1)
Change in trade working capital assets 14 (84) 31 (45)
Change in trade payables 13 21 7 17
Change in contract liabilities 3 29 (15) 6
Changes in trade working capital liabilities 15 50 (9) 23
Changes in trade working capital29(34)23(22)
Cash out for employee benefits(175)(155)(38)(53)
Cash out for provisions(26)(19)(8)(4)
Changes in lease portfolio (5) (10) (6) (1)
Changes in other working capital - 5 7 6
Cash settled operating derivatives (12) 16 (4) 16
Cash generated from operating activities70(3)55(8)
Income taxes paid (14) (16) (5) (6)
Net cash from / (used in) operating activities56(19)50(14)
Capital expenditure (26) (31) (9) (10)
Proceeds from sale of intangible assets and PP&E 11 9 8 2
Acquisition of subsidiaries, net of cash acquired (14) (20) (4) (7)
Interests received 2 2 1 1
Dividends received - - - -
Net cash from / (used in) investing activities(27)(41)(4)(14)


9M 2019

9M 2018

Q3 2019

Q3 2018

Interests paid (11) (10) (2) (4)
Dividends paid to non-controlling interests - (3) - (3)
Interests and dividends paid (11) (13) (2) (7)
Proceeds from borrowings 104 133 4 70
Repayment of borrowings (150) (34) (41) (27)
Payment of finance leases (32) - (12) -
Changes in borrowings(79)99(48)43
Proceeds / (payment) of derivatives 3 (1) 3 (8)
Other financing income / (costs) incurred (3) (2) (1) (1)
Net cash from/ used in financing activities(90)82(48)28
Net increase / (decrease) in cash & cash equivalents(61)23(2)-
Cash & cash equivalents at the start of the period136677687
Net increase / (decrease) in cash & cash equivalents (61) 23 (2) -
Effect of exchange rate fluctuations on cash held (4) (5) (3) (1)
Cash & cash equivalents at the end of the period (**)72857285

The Group has initially applied IFRS 16 at January 1, 2019, using the modified retrospective approach.

Under this approach, comparative information is not restated.

(*) Partially offset by 3 million Euro reversal of provision for onerous rent.

(**) Bank overdrafts are presented in minus of cash and cash equivalents in the cash flow statement: September 2019 9 million Euro, September 2018 10 million Euro.


Consolidated Statement of changes in Equity (in million Euro)

Unaudited, consolidated figures following IFRS accounting policies.

Attachments

  • CO_20191106_Q3_UK_final (https://ml-eu.globenewswire.com/Resource/Download/20609fa4-925e-4bd6-b49e-ae76893e8fdb)
  • Q3_2019_statements_UK (https://ml-eu.globenewswire.com/Resource/Download/658108aa-c93a-4427-8889-741f1b6cafbc)
  • CO_20191106_Q3_NL_final (https://ml-eu.globenewswire.com/Resource/Download/3d93e9c1-a1e6-4042-87ab-0f744e42c1ec)
  • Q3_2019_statements_NL (https://ml-eu.globenewswire.com/Resource/Download/7d80c622-cc1d-4ff1-a0a5-ea9006dcfe33)
Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2019 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.